Delve into the efficacy and safety data for the antibody–drug conjugates currently approved by the US FDA across tumor types such as hematologic, genitourinary, and gynecologic cancers.
Completion axillary lymph node dissection can be avoided in patients with early-stage, node-negative breast cancer with one or two macrometastases, show phase 3 data.
Ovarian function suppression plays a key role in the management of breast cancer, but it comes with potentially impactful and long-lasting side effects. Counselling and proactive management of these should be considered an essential part of survivorship care.
A holistic approach that takes into account all aspects of patient care – from treatment to nutrition, physical activity, and rehabilitation – could be a powerful tool to improve survival and quality of life in breast cancer.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
A woman developed sudden painless ecchymosis (bruising) of her breast, which was thought to be related to the radiotherapy she received for early-stage breast cancer a year and a half earlier.
Nasopharyngeal carcinoma is known for its high potential to metastasize, but breast metastasis is rare. The authors describe the first case of synchronous breast metastases in a male patient.
Mucoepidermoid carcinoma of the breast is a rare type of salivary gland-like tumor that generally displays a triple-negative phenotype. This case is the first to demonstrate HER2 gene amplification.
More than 2 million women are diagnosed with breast cancer worldwide every year, and the estimated 5-year prevalence is almost 8 million cases. In Europe, breast cancer is the most frequently occurring cancer, accounting for about 15% of all new …
Breast cancer remains the most prevalent malignancy affecting women in the USA [ 1 ]. Despite improvements in survival and quality-of-life, a subset of patients develop metastatic disease, which continues to be a leading cause of cancer-related …
Currently, the main clinical application of liquid biopsy (LB) in breast cancer (BC) is the circulating tumor DNA (ctDNA)-based detection of treatment targets in metastatic or advanced disease. In this short review we focus on clinically relevant …
Open AccessMetastasisSpecial Feature: Review Article
Accurate diagnosis of lymph node (LN) metastasis is vital for prognosis and treatment in patients with breast cancer. Imaging 1modalities such as ultrasound (US), MRI, CT, and 18F-FDG PET/CT are used for preoperative assessment. While conventional …
An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.
More than 2 million women are diagnosed with breast cancer worldwide every year, and the estimated 5-year prevalence is almost 8 million cases. In Europe, breast cancer is the most frequently occurring cancer, accounting for about 15% of all new …
Antihormonal therapy is one of the mainstays in the treatment of estrogen receptor (ER) positive breast cancer, comprising 70–80% of all cases. During the last two decades, aromatase inhibitors (AIs) of the “third generation” pushed aside earlier …
HER2-positive (HER2+) breast cancer accounts for approximately 20% of all breast cancers and is responsible for a substantial proportion of deaths. In the early-stage (neo)adjuvant chemotherapy plus the anti-HER2 trastuzumab has consistently shown …
Breast cancer remains the most prevalent malignancy affecting women in the USA [ 1 ]. Despite improvements in survival and quality-of-life, a subset of patients develop metastatic disease, which continues to be a leading cause of cancer-related …
